More U.S. insurers add Samsung Bioepis' Humira biosimilar to formulary listings

More U.S. insurers have included Samsung Bioepis’ Humira biosimilar Hadlima in their formulary listings, which could further boost sales in the $20 billion market.

2023-08-16

Samsung Bioepis ponders acquiring unit from U.S. partner Biogen

Samsung Bioepis is mulling the acquisition of a biosimilar business unit from its long-standing overseas partner Biogen, according to local media reports citing financial industry sources.

2023-08-02

Samsung Bioepis completes interchangeability study for Humira biosimilar

Samsung Bioepis’ Hadlima, a biosimilar of blockbuster autoimmune diseases drug Humira, met primary endpoints in the interchangeability test, the Incheon-based pharmaceutical company said Wednesday.

2023-08-02

Prime Therapeutics to cover Samsung Bioepis' Hadlima

Prime Therapeutics to cover Samsung Bioepis biosimilar of Humira

2023-07-13

Pharma firms scramble for slice of lucrative Humira market

A frenzied battle has begun between rival suppliers after the company behind Humira, the world’s top-selling drug for over a decade, lost its exclusive patent protection for the autoimmune treatment.

2023-07-03

Celltrion, Rani Therapeutics to jointly develop oral version of Adalimumab

Celltrion signed an agreement with California-based Rani Therapeutics to jointly develop an oral version of Adalimumab as part of efforts to tap into the approximately $20-billion market.

2023-06-05

Celltrion's biosimilar Yuflyma approved for sale in U.S.

Yuflyma, a Celltrion biosimilar of the autoimmune diseases drug Humira, was approved for sale in the United States.

2023-05-24

[ANALYSIS] Korean Humira biosimilars set for huge 2023

With Humira, the world’s top-selling drug for over a decade, losing its monopoly, Korean biosimilar makers are gearing up to tap into the approximately $20-billion market.

2023-02-19

Celltrion to sell Yuflyma in U.S. from July next year

Celltrion said Wednesday it has reached an agreement with AbbVie that allows it to sell its biosimilar product of Humira in the U.S. market starting July next year.

2022-04-27

Celltrion's CT-P17 biosimilar approved for use in Korea

Celltrion's CT-P17 biosimilar was approved for sale in Korea, the company said Friday.

2021-10-15

korea joongAng daily